A comprehensive overview of targeted therapy in metastatic renal cell carcinoma

Current Cancer Drug Targets

Volumn 12, Issue 7, 2012, Pages 857-872

  Mihaly Z ^a   Sztupinszki, Z ^a   Surowiak, P ^b   Gyorffy, B ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Biomarkers; Everolimus; Renal cell cancer; Sunitinib; Temsirolimus; Tyrosine kinase inhibitors

Indexed keywords

AFLIBERCEPT; ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; BRIVANIB; CALCIUM; CEDIRANIB; DOVITINIB; EVEROLIMUS; GEFITINIB; GLUCURONOSYLTRANSFERASE 1A1; HEMOGLOBIN; INTERFERON; INTERLEUKIN 2; IRINOTECAN; LACTATE DEHYDROGENASE; LINIFANIB; NAPTUMOMAB ESTAFENATOX; NIVOLUMAB; PAZOPANIB; RAMUCIRUMAB; REGORAFENIB; RILOTUMUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; TREBANANIB; UNINDEXED DRUG; VOLOCIXIMAB;

ABDOMINAL PAIN; ADVANCED CANCER; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BLEEDING; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CONSTIPATION; COUGHING; DECREASED APPETITE; DESQUAMATION; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRY SKIN; DYSPEPSIA; DYSPHONIA; DYSPNEA; EDEMA; EPISTAXIS; EXFOLIATIVE DERMATITIS; FATIGUE; FEVER; FOLLOW UP; GOLD STANDARD; HAIR COLOR; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFECTION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LACRIMATION DISORDER; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; OVERALL SURVIVAL; PAIN; PERIPHERAL EDEMA; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; RECOMMENDED DRUG DOSE; RECTUM HEMORRHAGE; RHINITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN DISCOLORATION; STOMATITIS; TASTE; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84864520788     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912802429265     Document Type: Article

References (88)

1. Weinstein, I. B. Cancer addiction to oncogenes--the Achilles heal of cancer. Science 2002, 297 (5578), 63-64.
2. Gyorffy, B.; Schafer, R. Biomarkers downstream of RAS: a search for robust transcriptional targets. Curr. Cancer Drug Targets. 2010, 10 (8), 858-868.
3. Mulders, P. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. BJU Int. 2009, 104 (11), 1585-1589.
4. Motzer, R. J.; Rini, B. I.; Bukowski, R. M.; Curti, B. D.; George, D. J.; Hudes, G. R.; Redman, B. G.; Margolin, K. A.; Merchan, J. R.; Wilding, G.; Ginsberg, M. S.; Bacik, J.; Kim, S. T.; Baum, C. M.; Michaelson, M. D. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006, 295 (21), 2516-2524.
5. Motzer, R. J.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Oudard, S.; Negrier, S.; Szczylik, C.; Pili, R.; Bjarnason, G. A.; Garcia-del-Muro, X.; Sosman, J. A.; Solska, E.; Wilding, G.; Thompson, J. A.; Kim, S. T.; Chen, I.; Huang, X.; Figlin, R. A. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009, 27 (22), 3584-3590.
6. Motzer, R. J.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Rixe, O.; Oudard, S.; Negrier, S.; Szczylik, C.; Kim, S. T.; Chen, I.; Bycott, P. W.; Baum, C. M.; Figlin, R. A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007, 356 (2), 115-124.
7. Motzer, R. J.; Hudes, G. R.; Ginsberg, M. S.; Baum, M. S.; Harmon, C. S.; Kim, S. T.; Chen, I.; Redman, B. G. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma. Am. J. Clin. Oncol. 2010, 33 (6), 614-618.
8. Pasche, B. A new strategy in the war on renal cell cancer: hitting multiple targets with limited collateral damage. JAMA. 2006, 295 (21), 2537-2538.
9. Stadler, W. M.; Szmulewitz, R. Z. Sunitinib--a new standard of care for metastatic renal cell carcinoma. Nat. Clin. Pract. Oncol. 2007, 4 (8), 458-459.
10. Escudier, B.; Eisen, T.; Stadler, W. M.; Szczylik, C.; Oudard, S.; Staehler, M.; Negrier, S.; Chevreau, C.; Desai, A. A.; Rolland, F.; Demkow, T.; Hutson, T. E.; Gore, M.; Anderson, S.; Hofilena, G.; Shan, M.; Pena, C.; Lathia, C.; Bukowski, R. M. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 2009, 27 (20), 3312-3318.
11. Faris, J. E.; Michaelson, M. D. Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC. Nat. Rev. Clin. Oncol. 2010, 7 (1), 7-8.
12. Escudier, B.; Eisen, T.; Stadler, W. M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A. A.; Rolland, F.; Demkow, T.; Hutson, T. E.; Gore, M.; Freeman, S.; Schwartz, B.; Shan, M.; Simantov, R.; Bukowski, R. M. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007, 356 (2), 125-134.
13. Arnault, J. P.; Wechsler, J.; Escudier, B.; Spatz, A.; Tomasic, G.; Sibaud, V.; Aractingi, S.; Grange, J. D.; Poirier-Colame, V.; Malka, D.; Soria, J. C.; Mateus, C.; Robert, C. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J. Clin. Oncol. 2009, 27 (23), e59-61.
14. Twardowski, P.; Figlin, R. A. What are the indications for sorafenib treatment in patients with renal cell carcinoma? Nat. Clin. Pract. Oncol. 2007, 4 (8), 456-457.
15. Fizazi, K.; Beuzeboc, P.; Lumbroso, J.; Haddad, V.; Massard, C.; Gross-Goupil, M.; Di Palma, M.; Escudier, B.; Theodore, C.; Loriot, Y.; Tournay, E.; Bouzy, J.; Laplanche, A. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J. Clin. Oncol. 2009, 27 (15), 2429-2435.
16. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26 (1), 127-132.
17. Kumar, R.; Crouthamel, M. C.; Rominger, D. H.; Gontarek, R. R.; Tummino, P. J.; Levin, R. A.; King, A. G. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br. J. Cancer 2009, 101 (10), 1717-1723.
18. Hutson, T. E.; Davis, I. D.; Machiels, J. P.; De Souza, P. L.; Rottey, S.; Hong, B. F.; Epstein, R. J.; Baker, K. L.; McCann, L.; Crofts, T.; Pandite, L.; Figlin, R. A. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2010, 28 (3), 475-480.
19. Sternberg, C. N. Pazopanib in renal cell carcinoma. Clin. Adv. Hematol. Oncol. 2010, 8 (4), 232-233.
20. Hoskins, J. M.; Goldberg, R. M.; Qu, P.; Ibrahim, J. G.; McLeod, H. L. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl. Cancer Inst. 2007, 99 (17), 1290-1295.
21. Xu, C. F.; Reck, B. H.; Xue, Z.; Huang, L.; Baker, K. L.; Chen, M.; Chen, E. P.; Ellens, H. E.; Mooser, V. E.; Cardon, L. R.; Spraggs, C. F.; Pandite, L. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br. J. Cancer 2010, 102 (9), 1371-1377.
22. Hudes, G.; Carducci, M.; Tomczak, P.; Dutcher, J.; Figlin, R.; Kapoor, A.; Staroslawska, E.; Sosman, J.; McDermott, D.; Bodrogi, I.; Kovacevic, Z.; Lesovoy, V.; Schmidt-Wolf, I. G.; Barbarash, O.; Gokmen, E.; O'Toole, T.; Lustgarten, S.; Moore, L.; Motzer, R. J.; Global, A. T. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007, 356 (22), 2271-2281.
23. Motzer, R. J.; Escudier, B.; Oudard, S.; Hutson, T. E.; Porta, C.; Bracarda, S.; Grunwald, V.; Thompson, J. A.; Figlin, R. A.; Hollaender, N.; Urbanowitz, G.; Berg, W. J.; Kay, A.; Lebwohl, D.; Ravaud, A.; Group, R.-S. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet 2008, 372 (9637), 449-456.
24. Knox, J. J. Progression-free survival as endpoint in metastatic RCC? Lancet 2008, 372 (9637), 427-429.
25. Molina AM F. D., Voss MH, Ginsberg MS, Baum MS, Brocks DR, Fischer PM, Trinos MJ, Patil S, Motzer RJ. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2012, 118(7), 1868-1876.
26. Negrier, S.; Gravis, G.; Perol, D.; Chevreau, C.; Delva, R.; Bay, J. O.; Blanc, E.; Ferlay, C.; Geoffrois, L.; Rolland, F.; Legouffe, E.; Sevin, E.; Laguerre, B.; Escudier, B. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol. 2011, 12 (7), 673-680.
27. Rini, B. I.; Escudier, B.; Tomczak, P.; Kaprin, A.; Szczylik, C.; Hutson, T. E.; Michaelson, M. D.; Gorbunova, V. A.; Gore, M. E.; Rusakov, I. G.; Negrier, S.; Ou, Y. C.; Castellano, D.; Lim, H. Y.; Uemura, H.; Tarazi, J.; Cella, D.; Chen, C.; Rosbrook, B.; Kim, S.; Motzer, R. J. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. Lancet 2011, 378 (9807), 1931-1939.
28. Rixe, O.; Bukowski, R. M.; Michaelson, M. D.; Wilding, G.; Hudes, G. R.; Bolte, O.; Motzer, R. J.; Bycott, P.; Liau, K. F.; Freddo, J.; Trask, P. C.; Kim, S.; Rini, B. I. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007, 8 (11), 975-984.
29. Rini, B. I.; Wilding, G.; Hudes, G.; Stadler, W. M.; Kim, S.; Tarazi, J.; Rosbrook, B.; Trask, P. C.; Wood, L.; Dutcher, J. P. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 2009, 27 (27), 4462-4468.
30. Bex A H. J. Tilting the AXIS towards therapeutic limits in renal cancer. Lancet 2011, 378(9807), 1898-1900.
31. Escudier, B.; Pluzanska, A.; Koralewski, P.; Ravaud, A.; Bracarda, S.; Szczylik, C.; Chevreau, C.; Filipek, M.; Melichar, B.; Bajetta, E.; Gorbunova, V.; Bay, J. O.; Bodrogi, I.; Jagiello-Gruszfeld, A.; Moore, N.; investigators, A. T. Bevacizumab plus interferon alfa- 2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370 (9605), 2103-2111.
32. Rini, B. I.; Halabi, S.; Rosenberg, J. E.; Stadler, W. M.; Vaena, D. A.; Ou, S. S.; Archer, L.; Atkins, J. N.; Picus, J.; Czaykowski, P.; Dutcher, J.; Small, E. J. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 2008, 26 (33), 5422-5428.
33. Rini, B. I.; Halabi, S.; Rosenberg, J. E.; Stadler, W. M.; Vaena, D. A.; Archer, L.; Atkins, J. N.; Picus, J.; Czaykowski, P.; Dutcher, J.; Small, E. J. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 2010, 28 (13), 2137-2143.
34. Sternberg, C. N. Antiangiogenic therapy in renal cell carcinoma: a plethora of choices. Nat. Clin. Pract. Urol. 2008, 5 (8), 422-423.
35. Feldman, D. R.; Baum, M. S.; Ginsberg, M. S.; Hassoun, H.; Flombaum, C. D.; Velasco, S.; Fischer, P.; Ronnen, E.; Ishill, N.; Patil, S.; Motzer, R. J. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009, 27 (9), 1432-1439.
36. Azad, N. S.; Posadas, E. M.; Kwitkowski, V. E.; Steinberg, S. M.; Jain, L.; Annunziata, C. M.; Minasian, L.; Sarosy, G.; Kotz, H. L.; Premkumar, A.; Cao, L.; McNally, D.; Chow, C.; Chen, H. X.; Wright, J. J.; Figg, W. D.; Kohn, E. C. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J. Clin. Oncol. 2008, 26 (22), 3709-3714.
37. Negrier, S.; Perol, D.; Ravaud, A.; Chevreau, C.; Bay, J. O.; Delva, R.; Sevin, E.; Caty, A.; Escudier, B.; For The French Immunotherapy, I. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007, 110 (11), 2468-2477.
38. Kabbinavar F.F. S. S., Hauke R. J, Amato R. J., Esteves W. B., Cotreau M. M., Strahs A. L., Bhargava P., Fishman M. N. Results from a phase I trial of tivozanib (AV-951) combined with temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC). J. Clin. Oncol. 2011, 29, 4549-4549.
39. Hsiao, Y. W.; Lin, Y. C.; Hui, R. C.; Yang, C. H. Fulminant acneiform eruptions after administration of dovitinib in a patient with renal cell carcinoma. J. Clin. Oncol. 2011, 29 (12), e340-341.
40. Forsberg, G.; Skartved, N. J.; Wallen-Ohman, M.; Nyhlen, H. C.; Behm, K.; Hedlund, G.; Nederman, T. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity. J. Immunother. 2010, 33 (5), 492-499.
41. Borghaei, H.; Alpaugh, K.; Hedlund, G.; Forsberg, G.; Langer, C.; Rogatko, A.; Hawkins, R.; Dueland, S.; Lassen, U.; Cohen, R. B. Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2009, 27 (25), 4116-4123.
42. Thompson, R. H.; Dong, H.; Lohse, C. M.; Leibovich, B. C.; Blute, M. L.; Cheville, J. C.; Kwon, E. D. PD-1 is expressed by tumorinfiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin. Cancer Res. 2007, 13 (6), 1757-1761.
43. Brahmer, J. R.; Drake, C. G.; Wollner, I.; Powderly, J. D.; Picus, J.; Sharfman, W. H.; Stankevich, E.; Pons, A.; Salay, T. M.; McMiller, T. L.; Gilson, M. M.; Wang, C.; Selby, M.; Taube, J. M.; Anders, R.; Chen, L.; Korman, A. J.; Pardoll, D. M.; Lowy, I.; Topalian, S. L. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 2010, 28 (19), 3167-3175.
44. Van Veldhuizen, P. J.; Hussey, M.; Lara, P. N., Jr.; Mack, P. C.; Gandour-Edwards, R.; Clark, J. I.; Lange, M. K.; Crawford, D. E. A Phase II Study of Gemcitabine and Capecitabine in Patients With Advanced Renal Cell Cancer: Southwest Oncology Group Study S0312. Am. J. Clin. Oncol. 2009, 32 (5), 453-459.
45. Gore, M. E.; Griffin, C. L.; Hancock, B.; Patel, P. M.; Pyle, L.; Aitchison, M.; James, N.; Oliver, R. T.; Mardiak, J.; Hussain, T.; Sylvester, R.; Parmar, M. K.; Royston, P.; Mulders, P. F. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an openlabel randomised trial. Lancet 2010, 375 (9715), 641-648.
46. Kraemer, A.; Hauser, S.; Kim, Y.; Gorschluter, M.; Muller, S. C.; Brossart, P.; Schmidt-Wolf, I. G. Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide. Ger. Med. Scie. 2009, 7, Doc04.
47. Srinivas, S.; Guardino, A. E. A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma. BJU Int. 2005, 96 (4), 536-539.
48. Olencki, T.; Malhi, S.; Mekhail, T.; Dreicer, R.; Elson, P.; Wood, L.; Bukowski, R. M. Phase I trial of thalidomide and interleukin-2 in patients with metastatic renal cell carcinoma. Invest. New Drugs 2006, 24 (4), 321-326.
49. Amato, R. J.; Morgan, M.; Rawat, A. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma. Cancer 2006, 106 (7), 1498-1506.
50. Amato, R. J.; Malya, R.; Rawat, A. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophagecolony stimulating factor in patients with metastatic renal cell carcinoma. Am J. Clin. Oncol. 2008, 31 (3), 237-243.
51. Harshman, L. C.; Li, M.; Srinivas, S. The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer. Am. J. Clin. Oncol. 2008, 31 (5), 417-423.
52. Choueiri, T. K.; Dreicer, R.; Rini, B. I.; Elson, P.; Garcia, J. A.; Thakkar, S. G.; Baz, R. C.; Mekhail, T. M.; Jinks, H. A.; Bukowski, R. M. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 2006, 107 (11), 2609-2616.
53. Patel, P. H.; Kondagunta, G. V.; Schwartz, L.; Ishill, N.; Bacik, J.; DeLuca, J.; Russo, P.; Motzer, R. J. Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. Invest. New Drugs 2008, 26 (3), 273-276.
54. Reyes-Reyes, E. M.; Teng, Y.; Bates, P. J. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res. 2010, 70 (21), 8617-8629.
55. Sonpavde, G.; Rosenberg, J. E.; Hahn, N. M.; Galsky, M. D.; Bangs, R.; Sternberg, C. N.; Vogelzang, N. J. Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma. J. Clin. Oncol. 2010, 28 (13), e205-207; author reply e208.
56. Jonasch, E.; Wood, C.; Tamboli, P.; Pagliaro, L. C.; Tu, S. M.; Kim, J.; Srivastava, P.; Perez, C.; Isakov, L.; Tannir, N. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br. J. Cancer 2008, 98 (8), 1336-1341.
57. Van Poppel, H.; Joniau, S.; Van Gool, S. W. Vaccine therapy in patients with renal cell carcinoma. Eur. Urol. 2009, 55 (6), 1333-1342.
58. Aass, N.; De Mulder, P. H.; Mickisch, G. H.; Mulders, P.; van Oosterom, A. T.; van Poppel, H.; Fossa, S. D.; de Prijck, L.; Sylvester, R. J. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J. Clin. Oncol. 2005, 23 (18), 4172-4178.
59. McShane, L. M.; Altman, D. G.; Sauerbrei, W.; Taube, S. E.; Gion, M.; Clark, G. M. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat. Clin. Pract. Urol. 2005, 2 (8), 416-422.
60. Swanton, C.; Larkin, J. M.; Gerlinger, M.; Eklund, A. C.; Howell, M.; Stamp, G.; Downward, J.; Gore, M.; Futreal, P. A.; Escudier, B.; Andre, F.; Albiges, L.; Beuselinck, B.; Oudard, S.; Hoffmann, J.; Gyorffy, B.; Torrance, C. J.; Boehme, K. A.; Volkmer, H.; Toschi, L.; Nicke, B.; Beck, M.; Szallasi, Z. Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med. 2010, 2 (8), 53.
61. Hoyle, M.; Green, C.; Thompson-Coon, J.; Liu, Z.; Welch, K.; Moxham, T.; Stein, K. Cost-effectiveness of sorafenib for secondline treatment of advanced renal cell carcinoma. Value Health 2010, 13 (1), 55-60.
62. Remak, E.; Charbonneau, C.; Negrier, S.; Kim, S. T.; Motzer, R. J. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J. Clin. Oncol. 2008, 26 (24), 3995-4000.
63. Hoyle, M.; Green, C.; Thompson-Coon, J.; Liu, Z.; Welch, K.; Moxham, T.; Stein, K. Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma. Value Health 2010, 13 (1), 61-68.
64. Kryston, T. B.; Georgiev, A. B.; Pissis, P.; Georgakilas, A. G. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat. Res. 2011, 711 (1-2), 193-201.
65. Ganesamoni, R.; Bhattacharyya, S.; Kumar, S.; Chauhan, A.; Mete, U. K.; Agarwal, M. M.; Mavuduru, R.; Kaushik, G.; Mandal, A. K.; Singh, S. K. Status of oxidative stress in patients with renal cell carcinoma. J. Urol. 2012, 187 (4), 1172-1176.
66. Fitzgerald, J. P.; Nayak, B.; Shanmugasundaram, K.; Friedrichs, W.; Sudarshan, S.; Eid, A. A.; DeNapoli, T.; Parekh, D. J.; Gorin, Y.; Block, K. Nox4 mediates renal cell carcinoma cell invasion through hypoxia-induced interleukin 6- and 8- production. PLoS One 2012, 7 (1), e30712.
67. Escudier, B.; Roigas, J.; Gillessen, S.; Harmenberg, U.; Srinivas, S.; Mulder, S. F.; Fountzilas, G.; Peschel, C.; Flodgren, P.; Maneval, E. C.; Chen, I.; Vogelzang, N. J. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 2009, 27 (25), 4068-4075.
68. Escudier, B.; Eisen, T.; Stadler, W. M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A. A.; Rolland, F.; Demkow, T.; Hutson, T. E.; Gore, M.; Freeman, S.; Schwartz, B.; Shan, M.; Simantov, R.; Bukowski, R. M.; Group, T. S. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007, 356 (2), 125-134.
69. Rini, B. I.; Michaelson, M. D.; Rosenberg, J. E.; Bukowski, R. M.; Sosman, J. A.; Stadler, W. M.; Hutson, T. E.; Margolin, K.; Harmon, C. S.; DePrimo, S. E.; Kim, S. T.; Chen, I.; George, D. J. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 2008, 26 (22), 3743-3748.
70. Porta, C.; Paglino, C.; De Amici, M.; Quaglini, S.; Sacchi, L.; Imarisio, I.; Canipari, C. Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinaseassociated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int. 2010, 77 (9), 809-815.
71. Kontovinis, L. F.; Papazisis, K. T.; Touplikioti, P.; Andreadis, C.; Mouratidou, D.; Kortsaris, A. H. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 2009, 9, 82.
72. Deprimo, S. E.; Bello, C. L.; Smeraglia, J.; Baum, C. M.; Spinella, D.; Rini, B. I.; Michaelson, M. D.; Motzer, R. J. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J. Transl. Med. 2007, 5, 32.
73. Garcia-Donas, J.; Esteban, E.; Leandro-Garcia, L. J.; Castellano, D. E.; del Alba, A. G.; Climent, M. A.; Arranz, J. A.; Gallardo, E.; Puente, J.; Bellmunt, J.; Mellado, B.; Martinez, E.; Moreno, F.; Font, A.; Robledo, M.; Rodriguez-Antona, C. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 2011, 12 (12), 1143-1150.
74. Kim, J. J.; Vaziri, S. A.; Rini, B. I.; Elson, P.; Garcia, J. A.; Wirka, R.; Dreicer, R.; Ganapathi, M. K.; Ganapathi, R. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 2012, 118 (7), 1946-1954.
75. Perez-Gracia, J. L.; Prior, C.; Guillen-Grima, F.; Segura, V.; Gonzalez, A.; Panizo, A.; Melero, I.; Grande-Pulido, E.; Gurpide, A.; Gil-Bazo, I.; Calvo, A. Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br. J. Cancer 2009, 101 (11), 1876-1883.
76. Huang, D.; Ding, Y.; Zhou, M.; Rini, B. I.; Petillo, D.; Qian, C. N.; Kahnoski, R.; Futreal, P. A.; Furge, K. A.; Teh, B. T. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 2010, 70 (3), 1063-1071.
77. Pena, C.; Lathia, C.; Shan, M.; Escudier, B.; Bukowski, R. M. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin. Cancer Res. 2010, 16 (19), 4853-4863.
78. Choueiri, T. K.; Regan, M. M.; Rosenberg, J. E.; Oh, W. K.; Clement, J.; Amato, A. M.; McDermott, D.; Cho, D. C.; Atkins, M. B.; Signoretti, S. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factortargeted therapy. BJU Int. 2010, 106 (6), 772-778.
79. Hutson T. E. D. I. D., Machiels J. H., de Souza P. L., Baker K., Bordogna W., Westlund R., Crofts T., Pandite L., Figlin R. A. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multikinase angiogenesis inhibitor. J. Clin. Oncol. 2008, 26, 5046.
80. Xu, C. F.; Bing, N. X.; Ball, H. A.; Rajagopalan, D.; Sternberg, C. N.; Hutson, T. E.; de Souza, P.; Xue, Z. G.; McCann, L.; King, K.S.; Ragone, L. J.; Whittaker, J. C.; Spraggs, C. F.; Cardon, L. R.; Mooser, V. E.; Pandite, L. N. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J. Clin. Oncol. 2011, 29 (18), 2557-2564.
81. Armstrong AJ G. D., Halabi S. Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma (RCC). J. Clin. Oncol. 2010, 28 (15 Suppl), 4631.
82. Cho, D.; Signoretti, S.; Dabora, S.; Regan, M.; Seeley, A.; Mariotti, M.; Youmans, A.; Polivy, A.; Mandato, L.; McDermott, D.; Stanbridge, E.; Atkins, M. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin. Genitourin. Cancer 2007, 5 (6), 379-385.
83. Choueiri, T. K.; Vaziri, S. A.; Jaeger, E.; Elson, P.; Wood, L.; Bhalla, I. P.; Small, E. J.; Weinberg, V.; Sein, N.; Simko, J.; Golshayan, A. R.; Sercia, L.; Zhou, M.; Waldman, F. M.; Rini, B. I.; Bukowski, R. M.; Ganapathi, R. Von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J. Urol. 2008, 180 (3), 860-865; discussion 865-866.
84. Atkins, M.; Regan, M.; McDermott, D.; Mier, J.; Stanbridge, E.; Youmans, A.; Febbo, P.; Upton, M.; Lechpammer, M.; Signoretti, S. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. 2005, 11 (10), 3714-3721.
85. Sabatino, M.; Kim-Schulze, S.; Panelli, M. C.; Stroncek, D.; Wang, E.; Taback, B.; Kim, D. W.; Deraffele, G.; Pos, Z.; Marincola, F. M.; Kaufman, H. L. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J. Clin. Oncol. 2009, 27 (16), 2645-2652.
86. Maruyama, R.; Yamana, K.; Itoi, T.; Hara, N.; Bilim, V.; Nishiyama, T.; Takahashi, K.; Tomita, Y. Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma. Br. J. Cancer 2006, 95 (9), 1244-1249.
87. Miyake, H.; Sakai, I.; Muramaki, M.; Kurahashi, T.; Takenaka, A.; Fujisawa, M. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens. Int J.Urol. 2009, 16 (5), 465-471.
88. Rini, B. I.; Weinberg, V.; Dunlap, S.; Elchinoff, A.; Yu, N.; Bok, R.; Simko, J.; Small, E. J. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer 2006, 106 (3), 566-575.